Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3391181 | Seminarios de la Fundación Española de Reumatología | 2006 | 11 Pages |
Abstract
The antiphospholipid syndrome (APS) is a well known cause of pregnancy complications, including maternal thrombosis and preeclampsia as well as embryofetal losses. A multidisciplinary, medical-obstetric approach is of great importance in the clinical management of pregnant women with APS. Therapeutic interventions are based on the combination acilsalycilic acid-heparin. Although the specific combinations in different situations are still a matter of debate - due to important limitations of the available studies-, combined treatment with both drugs is usually recommended in women with previous thrombosis and/or fetal death. Aspirin alone is still a reasonable option for women with early losses, although controversy is particularly important in this group. In any situation, an adequate thromboprophylaxis in the peripartum period is warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Immunology, Allergology and Rheumatology
Authors
Irama Villar, Guillermo Ruiz-Irastorza,